{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:59:02Z","timestamp":1772989142969,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":448,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009340","name":"Children's Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jtct.2021.12.016","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T03:42:22Z","timestamp":1640317342000},"page":"174.e1-174.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease"],"prefix":"10.1016","volume":"28","author":[{"given":"Niketa C.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sweta","family":"Bhoopatiraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allistair","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-3102","authenticated-orcid":false,"given":"Eric","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Andreansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff D.E.","family":"Cuvelier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamar","family":"Godder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2056-5167","authenticated-orcid":false,"given":"Michael","family":"Grimley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Hale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naynesh","family":"Kamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jacobsohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Ngwube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi","family":"Skiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lolie C.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.12.016_bib0001","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJM199706193362502","article-title":"Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia","volume":"336","author":"Hartmann","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.12.016_bib0002","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1200\/JCO.2006.06.1663","article-title":"Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation","volume":"24","author":"Dekker","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.12.016_bib0003","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.bbmt.2020.08.013","article-title":"The effect of granulocyte colony-stimulating factor use on hospital length of stay after allogeneic hematopoietic cell transplantation: a retrospective multicenter cohort study","volume":"26","author":"George","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.016_bib0004","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10739680802279394","article-title":"Sickle red cell-endothelium interactions","volume":"16","author":"Kaul","year":"2009","journal-title":"Microcirculation"},{"key":"10.1016\/j.jtct.2021.12.016_bib0005","first-page":"482","article-title":"Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease","volume":"111","author":"Abboud","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.12.016_bib0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3233\/CH-189012","article-title":"Inflammation in sickle cell disease","volume":"68","author":"Conran","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.jtct.2021.12.016_bib0007","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtct.2021.12.016_bib0008","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2021.12.016_bib0009","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1182\/blood.V97.10.3313","article-title":"Fatal sickle cell crisis after granulocyte colony-stimulating factor administration","volume":"97","author":"Adler","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.016_bib0010","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V97.12.3998","article-title":"Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell\/beta+ thalassemia","volume":"97","author":"Grigg","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.016_bib0011","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.12.016_bib0012","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.016_bib0013","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/bloodadvances.2016002972","article-title":"Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT","volume":"1","author":"Fitzhugh","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.12.016_bib0014","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbmt.2018.03.031","article-title":"Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease","volume":"24","author":"Saraf","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.016_bib0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2021.12.016_bib0016","first-page":"3894","article-title":"Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease","volume":"4","author":"Ngwube","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.12.016_bib0017","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.016_bib0018","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.016_bib0019","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2021.12.016_bib0020","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.bbmt.2017.05.027","article-title":"Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.016_bib0021","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.pcl.2009.11.007","article-title":"Management of acute graft-versus-host disease in children","volume":"57","author":"Carpenter","year":"2010","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.jtct.2021.12.016_bib0022","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.2020005687","article-title":"Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease","volume":"136","author":"Brazauskas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.016_bib0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2021.12.016_bib0024","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres","volume":"192","author":"Alzahrani","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.12.016_bib0025","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41409-018-0208-3","article-title":"Peripheral hematopoietic stem cell mobilization utilizing growth factors in donors with sickle cell trait is safe and effective","volume":"53","author":"Damlaj","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.016_bib0026","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/trf.13551","article-title":"Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait","volume":"56","author":"Panch","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2021.12.016_bib0027","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jca.21566","article-title":"Granulocyte-colony stimulating factor administration among hemoglobin S trait donors: a single center experience from the Eastern Mediterranean region","volume":"33","author":"Gereklioglu","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jtct.2021.12.016_bib0028","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.2017.187047","article-title":"Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results","volume":"103","author":"Boulad","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.12.016_bib0029","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.190876","article-title":"Hematopoietic stem cell mobilization with plerixafor in sickle cell disease","volume":"103","author":"Hsieh","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.12.016_bib0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1824-7288-36-14","article-title":"High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome","volume":"36","author":"No\u00e8","year":"2010","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.jtct.2021.12.016_bib0031","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/pbc.21812","article-title":"Reversible posterior leuko-encephalopathy in children with sickle cell disease","volume":"52","author":"Khademian","year":"2009","journal-title":". Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2021.12.016_bib0032","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood.V85.4.879.bloodjournal854879","article-title":"Neurologic complications after allogeneic marrow transplantation for sickle cell anemia","volume":"85","author":"Walters","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.016_bib0033","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.idc.2019.02.011","article-title":"Bacterial infections in the stem cell transplant recipient and hematologic malignancy patient","volume":"33","author":"Misch","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jtct.2021.12.016_bib0034","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/bmt.2017.14","article-title":"Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis","volume":"52","author":"Dandoy","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.016_bib0035","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.bbmt.2016.06.002","article-title":"Healthcare burden, risk factors, and outcomes of mucosal barrier injury laboratory-confirmed bloodstream infections after stem cell transplantation","volume":"22","author":"Dandoy","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.016_bib0036","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/bmt.2014.37","article-title":"Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients","volume":"49","author":"Gudiol","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.016_bib0037","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","article-title":"Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection","volume":"147","author":"Sung","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2021.12.016_bib0038","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"issue":"suppl","key":"10.1016\/j.jtct.2021.12.016_bib0039","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.bbmt.2019.12.085","article-title":"Abatacept for GVHD prophylaxis after hematopoietic cell transplantation (HCT) for pediatric sickle cell disease (SCD): A Sickle Cell Transplant Advocacy and Research Alliance (STAR) trial","volume":"26","author":"Chaudhury","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721014494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721014494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:01:21Z","timestamp":1763002881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721014494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2666636721014494"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.12.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}